目的 观察阿瑞匹坦对减轻化疗所致恶心呕吐的疗效及安全性。方法 将80例接受含顺铂化疗患者随机分为观察组和对照组, 观察组采用阿瑞匹坦与昂丹司琼、地塞米松联合止吐, 对照组采用帕洛诺司琼与昂丹司琼、地塞米松联合止吐, 观察两组疗效及不良反应。结果 观察组呕吐的完全缓解率和恶心控制率分别为80%和77.5%,优于对照组的47.5%和37.5%,皆有统计学意义(P<0.01)。两组中出现最多的不良反应主要有便秘、腹泻、呃逆、食欲减退、疲乏、失眠、转氨酶升高等, 均为轻度。结论 阿瑞匹坦对化疗所致恶心呕吐有明显的预防作用,且不良反应轻,具有临床应用前景。
Abstract
Objective To observe the curative effect and adverse reaction of aprepitant in alleviating nausea and vomiting caused by chemotherapy. Methods 80 patients with cisplatin chemotherapy were randomly divided into study group and control group. The study group used aprepitant combined with the ondansetron hydrochloride, dexamethasone. The control group received palonosetron hydrochlorid combined with ondansetron hydrochloride, and dexamethasone. The curative effect and adverse reactions in the two groups were observed. Results In the study group, complete remission rate and nausea vomiting control rates were 80% and 77.5% respectively, compared with 47.5% and 37.5% in the control group, there was statistically significant difference (P＜0.01). In the two groups, the most adverse reactions mainly included constipation, diarrhea, hiccups, anorexia, fatigue, insomnia, transaminase and elevation, were mild. Conclusions Aprepitant has obvious preventive effect on chemotherapy induced nausea and vomiting, and has clinical application prospects.
关键词
阿瑞匹坦 /
化疗 /
呕吐
Key words
aprepitant /
chemotherapy /
vomiting
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ettinger D S,Bierman P J,Bradbury B, et al. Antiemesis[J]. J Natl Compr Canc Netw,2007,5(1):12-33.
[2] Richardson J L, Marks G, Levine A .The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy[J]. J Clin Oncol,1988,6(11):1746-1752.
[3] Bloechl-Daum B, Deuson R R, Mavros P, et al.Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment[J].J Clin Oncol,2006,24(27):4472-4478.
[4] Martin A R, Pearson J D, Cai B, et al . Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall[J]. Support Care Cancer,2003,11:522-527.
[5] 中国抗癌协会癌症康复与姑息治疗专业委员会. 肿瘤治疗相关呕吐防治指南[M].北京: 中国协和医科大学出版社,2009: 20-42.
[6] Saito M,Aogi K,Sekine L,et al.Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial[J]. Lancet Oncol,2009,10(2):115-124.
[7] Cubeddu L X. Serotonin mechanisms in chemotherapy- induced emesis in cancer patients[J].Oncology,1996, 1:18-25 .
[8] Wolf H. Preclinical and clinical pharmacology of the 5- HT3 receptor antagonists[J].Scand J Rheumatol Suppl,2000,113:37-45.
[9] 张晓静,张 频.肿瘤化疗所致恶心呕吐的发生机制和药物治疗的研究进展[J].癌症进展,2006,4(4):348-354.
[10] Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference[J]. Ann Oncol, 2010,21(5):232-243.
[11] Basch E, Prestrud A A, Hesketh P J, et al. Antiemetic American Society Clinical Oncology clinical practice guideline update[J].J Clin Oncol, 2011,29:4189-4198.
[12] NCCN Clinical Practice Guidelines in Oncology version 1 2014. Antiemesis[M]. National Comprehensive Cancer Network (NCCN),2014.
[13] Warr D G,Grunberg S M,Gralla R J, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea andvomiting:Pooled data from 2 randomised, double-blind, placebo controlled trials[J].Eur J Cancer,2013,41(9):1278-1285.
PDF(517 KB)
